

HEDIS MEASURE OVERVIEW

Prenatal Immunization Status (PRS-E)

Prenatal Immunization Status (PRS-E) is an important preventive measure for your patients' health, and it's one of the Healthcare Effectiveness Data and Information Set (HEDIS®) performance measures used to evaluate the care and services provided by healthcare providers.

Please note: The information offered in this flyer is based on HEDIS technical specifications. It is not meant to preclude your clinical judgment.





The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) recommends pregnant patients receive one flu vaccination during any trimester and one tetanus, diphtheria, toxoids and acellular pertussis (Tdap) vaccine during the early part of gestational weeks 27–36 to protect themselves and their baby. More information can be found at www.cdc.gov/vaccines/pregnancy.

Who is included in the PRS-E measure?

Patients with a pregnancy episode in which the delivery date occurs during the measurement period of Jan. 1–Dec. 31 are included. The denominator for this measure is based on deliveries, not on patients.

Pregnant patients who deliver after 37 weeks:

- Immunization status: Influenza
 - Deliveries in which patients received an adult influenza vaccine on or between July 1 of the year prior to the measurement period and the delivery date **or**
 - Deliveries in which patients had anaphylaxis due to the influenza vaccine on or before the delivery date
- Immunization status: Tdap
 - Deliveries in which patients received at least one Tdap vaccine during pregnancy (including the delivery date) **or**
 - Deliveries in which patients had anaphylaxis or encephalitis due to the Tdap vaccine on or before the delivery date
- Immunization status: Combination
 - Deliveries that met criteria for both influenza and Tdap



Exclusions

Unless otherwise indicated, these apply to commercial and Medicaid patients.

- Deliveries that occurred less than 37 weeks gestation
- Deliveries in which patients were in hospice or using hospice services anytime during the measurement period

Performing well on the PRS-E measure

To address and satisfy the PRS-E measure, patients must have received influenza and Tdap vaccinations.

Measure best practices

- Vaccinate patients during prenatal visits or when admitted for delivery.
- Ensure complete and accurate documentation and coding.

Coding for the PRS-E measure

CVX code	Adult Influenza Immunization: 88, 135, 140–141, 144, 150, 153, 155, 158, 166, 168, 171, 185–186, 197, 205, 320
CPT code	Adult Influenza Vaccine Procedure: 90630, 90653–90654, 90656, 90658, 90661–90662, 90673–90674, 90682, 90686, 90688–90689, 90694, 90756
CVX code	Tdap Immunization: 115
CPT code	Tdap Vaccine Procedure: 90715

Information regarding inclusion, compliance and exclusions for this measure were sourced from the HEDIS Measurement Year 2025: Volume 2: Technical Specifications for Health Plans report. The coding information in this document is subject to changing requirements and should not be relied on as official coding or legal advice. All coding should be considered on a case-by-case basis and supported by medical necessity and appropriate documentation in the medical record.

Coding included above is based on the NCQA Value Set, but each state's fee schedule determines which codes are reimbursed. Please consult your respective state's fee schedule for reimbursement information.

NCQA copyright notice and disclaimer

The HEDIS measure specifications were developed by and are owned by NCQA. The HEDIS measure specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measure specifications. NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute a modification. Any commercial use and/or internal or external reproduction, distribution and publication must be approved by NCQA and are subject to a license at the discretion of NCQA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA's Measure Certification Program. Reprinted with permission by NCQA. © 2026 NCQA, all rights reserved.

Limited proprietary coding is contained in the measure specifications for convenience. NCQA disclaims all liability for use or accuracy of any third-party code values contained in the specifications.

The full text of this notice and disclaimer is available here:

[https://assets.humana.com/is/content/humana/NCQA copyright notice and disclaimerpdf](https://assets.humana.com/is/content/humana/NCQA%20copyright%20notice%20and%20disclaimer.pdf)